Medivation (MDVN), Astellas Issue Update on Enzalutamide Phase 3
Tweet
Share
E-mailGet Alerts MDVN Hot Sheet
Join SI Premium – FREE
Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. announced that new data for enzalutamide (XTANDI capsules), an oral androgen receptor inhibitor, were presented at the 2012 European Society of Medical Oncology (ESMO) Annual Meeting in Vienna, Austria. The data from the randomized, global, placebo-controlled phase 3 AFFIRM study highlight the effect of enzalutamide on pain-related secondary endpoints and a post hoc analysis of the survival impact of baseline corticosteroid use among men with advanced prostate cancer.
"Findings from the corticosteroid analysis showed that patients in both the enzalutamide and the placebo groups taking glucocorticoids had an inferior survival compared to those who did not take glucocorticoids," said Dr. Howard I. Scher, chief, Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, and co-principal investigator for AFFIRM. "Patients on enzalutamide fared better than those on placebo whether or not they were taking corticosteroids, which confirmed the survival benefit associated with enzalutamide while suggesting the impact of corticosteroids on outcomes be explored further."
"Additionally, the pain-related data presented today provide additional information to help those of us who treat prostate cancer on a daily basis to assess the benefits of enzalutamide for the individual patients," Scher said.
"Findings from the corticosteroid analysis showed that patients in both the enzalutamide and the placebo groups taking glucocorticoids had an inferior survival compared to those who did not take glucocorticoids," said Dr. Howard I. Scher, chief, Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, and co-principal investigator for AFFIRM. "Patients on enzalutamide fared better than those on placebo whether or not they were taking corticosteroids, which confirmed the survival benefit associated with enzalutamide while suggesting the impact of corticosteroids on outcomes be explored further."
"Additionally, the pain-related data presented today provide additional information to help those of us who treat prostate cancer on a daily basis to assess the benefits of enzalutamide for the individual patients," Scher said.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Cytek faces $56M damages award in Beckman Coulter patent case
- Solowin Holdings marks 10 years, expands into stablecoins and AI
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
